Madrigal Pharmaceuticals, Inc. (MDGL)
427.18
+1.97
(+0.46%)
USD |
NASDAQ |
Nov 13, 16:00
427.18
0.00 (0.00%)
After-Hours: 19:59
Madrigal Pharmaceuticals Enterprise Value : 9.267B for Nov. 12, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 12, 2026 | 9.267B |
| November 11, 2026 | 9.448B |
| November 10, 2026 | 9.438B |
| November 09, 2026 | 9.443B |
| November 06, 2026 | 8.673B |
| November 05, 2026 | 8.683B |
| November 04, 2026 | 8.691B |
| November 03, 2026 | 8.596B |
| November 02, 2026 | 9.405B |
| October 30, 2026 | 9.386B |
| October 29, 2026 | 9.417B |
| October 28, 2026 | 9.401B |
| October 27, 2026 | 9.618B |
| October 26, 2026 | 9.558B |
| October 23, 2026 | 9.476B |
| October 22, 2026 | 9.920B |
| October 21, 2026 | 10.03B |
| October 20, 2026 | 10.25B |
| October 19, 2026 | 9.775B |
| October 16, 2026 | 9.836B |
| October 15, 2026 | 10.07B |
| October 14, 2026 | 10.07B |
| October 13, 2026 | 9.891B |
| October 12, 2026 | 10.24B |
| October 09, 2026 | 10.35B |
| Date | Value |
|---|---|
| October 08, 2026 | 10.47B |
| October 07, 2026 | 10.72B |
| October 06, 2026 | 10.92B |
| October 05, 2026 | 10.86B |
| October 02, 2026 | 10.99B |
| October 01, 2026 | 11.00B |
| September 30, 2026 | 11.10B |
| September 29, 2026 | 11.27B |
| September 28, 2026 | 11.45B |
| September 25, 2026 | 11.44B |
| September 24, 2026 | 11.36B |
| September 23, 2026 | 11.36B |
| September 22, 2026 | 11.49B |
| September 21, 2026 | 11.56B |
| September 18, 2026 | 11.78B |
| September 17, 2026 | 11.85B |
| September 16, 2026 | 11.73B |
| September 15, 2026 | 11.59B |
| September 14, 2026 | 11.98B |
| September 11, 2026 | 11.85B |
| September 10, 2026 | 11.82B |
| September 09, 2026 | 12.13B |
| September 08, 2026 | 11.84B |
| September 04, 2026 | 12.00B |
| September 03, 2026 | 12.04B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Insmed, Inc. | 25.50B |
| Alnylam Pharmaceuticals, Inc. | 20.38B |
| Arrowhead Pharmaceuticals, Inc. | 6.429B |
| Cytokinetics, Inc. | 7.958B |
| United Therapeutics Corp. | 23.08B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 55.44M |
| Revenue (Quarterly) | 431.27M |
| Total Expenses (Quarterly) | 375.83M |
| EPS Diluted (Quarterly) | 1.829 |
| Gross Profit Margin (Quarterly) | 91.14% |
| Profit Margin (Quarterly) | 12.86% |
| Earnings Yield | -1.40% |
| Normalized Earnings Yield | -1.399 |